References

ophthalmology

Офтальмология

Ophthalmology in Russia

1816-50952500-0845

Ophthalmology

10.18008/1816-5095-2020-4-676-682

ophthalmology-1357

Research Article

ОБЗОРЫ

REVIEWS

Ингибиторы карбоангидразы в лечении глаукомы. Обзор. Часть 2

Carbonic Anhydrase Inhibitors in the Treatment of Glaucoma. Review. Part II

Курышева

Н. И.

Kurysheva

N. I.

доктор медицинских наук, профессор, заведующая кафедрой;

руководитель консультативно-диагностического отдела,

ул. Гамалеи, 15, Москва, 123098

MD., Professor, head of the consultative and diagnostic department,

15 Gamalei str., Moscow, 123098

Медико-биологический университет инноваций и непрерывного образования ФГБУ ГНЦ РФ «Федеральный биофизический центр им. А.И. Бурназяна» Федерального медико-биологического агентства России; Консультативно-диагностический отдел Центра офтальмологии Федерального медико-биологического агентства РоссииРоссияThe Department of Eye Diseases at the Medical Biological University of Innovations and Continuing Education of the A.I. Burnasyan Federal Medical Biophysical Center of the Federal Medical Biological Agency (FMBA); Diagnostic Department of the Ophthalmological Center of FMBA of Russia, Clinical Hospital No. 86Russian Federation

2020

24122020

174676682

2020

Курышева Н.И.

Kurysheva N.I.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.ophthalmojournal.com/opht/article/view/1357

Местные и системные ингибиторы карбоангидразы (ИКА) широко применяются в лечении глаукомы как препараты, эффективно снижающие офтальмотонус. В данной части обзора приводится характеристика системных ИКА, их побочные действия, пути их преодоления, а также противопоказания к использованию. Рассмотрены возможности применения ИКА при беременности. Особое внимание уделено антиоксидантным свойствам ИКА и перспективным разработкам гибридных форм на основе существующих ИКА в рамках многоцелевой стратегии в лечении глаукомы.

Topical and systemic carbonic anhydrase inhibitors (CAIs) are widely used in the treatment of glaucoma for reducing intraocular pressure. This part of the review describes the characteristics of systemic CAIs, their side effects and the ways to overcome them, as well as contraindications. The use of CAIs during pregnancy is considered. Particular attention is paid to the antioxidant activity of CAIs and the promising development of hybrid forms based on the existing CAIs as a part of a multipurpose glaucoma treatment strategy.

ингибиторы карбоангидразыглаукомапобочные действиябеременностьантиоксидантная активностьводянистая влагамногоцелевая стратегия в лечении глаукомы

carbonic anhydrase inhibitorsglaucomaside effectspregnancyantioxidant activityaqueous humormultipurpose glaucoma treatment strategy

References1

Javaheri S. Acetazolamide improves central sleep apnea in heart failure: a doubleblind, prospective study. Am. J. Respir. Crit. Care Med. 2006 Jan 15;173(2):234–237. DOI: 10.1164/rccm.200507-1035OC

Van Berkel M.A., Elefritz J.L. Evaluating off-label uses of acetazolamide. Am J Health Syst Pharm. 2018 Apr 15;75(8):524–531. DOI: 10.2146/ajhp170279

Leaf D.E., Goldfarb D.S. Mechanisms of action of acetazolamide in the prophylaxis and treatment of acute mountain sickness. J. Appl. Physiol. 2007 Apr;102(4):1313– 1322. DOI: 10.1152/japplphysiol.01572.2005

Supuran C.T. Drug interaction considerations in the therapeutic use of carbonic anhydrase inhibitors. Expert Opin Drug Metab Toxicol. 2016;12(4):423–431. DOI: 10.1517/17425255.2016.1154534

Masini E., Carta F., Scozzafava A., Supuran C.T. Antiglaucoma carbonic anhydrase inhibitors: a patent review. Expert Opin Ther Pat. 2013;23(6):705–716. DOI: 10.1517/13543776.2013.794788

LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. National Institute of Diabetes and Digestive and Kidney Diseases; Bethesda (MD): Oct 2, 2017. Carbonic Anhydrase Inhibitors. PMID: 31643176

Ghorai S., Pulya S., Ghosh K., Panda P., Ghosh B., Gayen S. Structure-activity relationship of human carbonic anhydrase-II inhibitors: Detailed insight for future development as anti-glaucoma agents. Bioorg. Chem. 2020 Jan;95:103557. DOI: 10.1016/j.bioorg.2019.103557

Her Y., Kil M.S., Park J.H., Kim C.W., Kim S.S. Stevens-Johnson syndrome induced by acetazolamide. J. Dermatol. 2011 Mar;38(3):272–275. DOI: 10.1111/j.13468138.2010.00921.x

Sall K. The efficacy and safety of brinzolamide 1% ophthalmic suspension (Azopt) as a primary therapy in patients with open-angle glaucoma or ocular hypertension. Brinzolamide Primary Therapy Study Group. Surv Ophthalmol. 2000;44(Suppl 2):S155–S162. DOI: 10.1016/s0039-6257(99)00107-1

Silver L.H. Ocular comfort of brinzolamide 1.0% ophthalmic suspension compared with dorzolamide 2.0% ophthalmic solution: results from two multicenter comfort studies. Brinzolamide Comfort Study Group. Surv Ophthalmol. 2000;44(Suppl 2):S141–S145. DOI: 10.1016/s0039-6257(99)00111-3

Michaud J.E, Friren B. International Brinzolamide Adjunctive Study Group. Comparison of topical brinzolamide 1% and dorzolamide 2% eye drops given twice daily in addition to timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2001;132(2):235–243. DOI: 10.1016/s0002-9394(01)00974-6

Barnebey H., Kwok S.Y. Patients’ acceptance of a switch from dorzolamide to brinzolamide for the treatment of glaucoma in a clinical practice setting. Clin Ther. 2000;22(10):1204–1212. DOI: 10.1016/s0149-2918(00)83063-5

Auger G.A., Raynor M., Longstaff S. Patient perspectives when switching from Cosopt® (dorzolamide-timolol) to AzargaTM (brinzolamide-timolol) for glaucoma requiring multiple drug therapy. Clin Ophthalmol. 2012;6:2059–2062. DOI: 10.2147/OPTH.S33254

Manni G., Denis P., Chew P. The safety and efficacy of brinzolamide 1%/timolol 0.5% fixed combination versus dorzolamide 2%/timolol 0.5% in patients with openangle glaucoma or ocular hypertension. J Glaucoma. 2009;18(4):293–300. DOI: 10.1097/IJG.0b013e31818fb434

Newman-Casey P., Niziol L., Gillespie B. The Association between Medication Adherence and Visual Field Progression in the Collaborative Initial Glaucoma Treatment Study Ophthalmology 2020 (article in press). DOI: 1016/j.ophtha.2019.10.022 1 ISSN 0161-6420/19

Robin A., Grover D. Compliance and adherence in glaucoma management Indian J Ophthalmol. 2011;59(Suppl 1):S93–S96. DOI: 10.4103/0301-4738.73693

Djafari F., Lesk M.R., Harasymowycz P.J., Desjardins D., Lachaine J. Determinants of adherence to glaucoma medical therapy in a long-term patient population. J Glaucoma. 2009;18(3):238–243. DOI: 10.1097/IJG.0b013e3181815421

Altafini R., Scherzer M., Frezzotti P. Brinzolamide 1%/timolol versus dorzolamide 2%/ timolol in the treatment of open-angle glaucoma or ocular hypertension: prospective randomized patient-preference study. Clinical Ophthalmology 2015;9:2263–2270. DOI: 10.2147/OPTH.S88891

Lanzl I., Raber T. Efficacy and tolerability of the fixed combination of brinzolamide 1% and timolol 0.5% in daily practice. Clin Ophthalmol. 2011;5:291–298. DOI: 10.2147/OPTH.S16355

Hutnik С., Neima D., Ibrahim N. Tolerability and effectiveness of preservative-free dorzolamide–timolol (preservative-free COSOPT®) in patients with open-angle glaucoma or ocular hypertension. Clinical Ophthalmology 2010;4:581–590.

Kwon J., Heo J., Kim H., Song J. Comparison of Cytotoxic Effects on Rabbit Corneal Endothelium between Preservative-free and Preservative-containing Dorzolamide/ timolol Korean J Ophthalmol 2015;29(5):344–350. DOI: 10.3341/kjo.2015.29.5.344

Pinto L., Vandewalle E., Gerlier L., Stalmans I. Improvement in Glaucoma Patient Quality of Life by Therapy Switch to Preservative-Free Timolol/Dorzolamide Fixed Combination Ophthalmologica 2014;231:166–171. DOI: 10.1159/000356468

Ozawa H., Azuma E., Shindo K., Higashigawa M., Mukouhara R., Komada Y. Transient renal tubular acidosis in a neonate following transplacental acetazolamide. Eur J Pediatr. 2001;160(5):321–322. DOI: 10.1007/pl00008441

Worsham F. Jr, Beckman E.N., Mitchell E.H. Sacrococcygeal teratoma in a neonate association with maternal use of acetazolamide. JAMA 1978;240 (3):251–252.

Weaver T.E., Scott W.J. Jr. Acetazolamide teratogenesis: interaction of maternal metabolic and respiratory acidosis in the induction of ectrodactyly in C57BL/6J mice. Teratology 1984;30(2):195–202. DOI: 10.1002/tera.1420300207

Sethi H.S., Naik M., Gupta V.S. Management of glaucoma in pregnancy: risks and choices, a dilemma? Int J Ophthalmol 2016;9(11):1684–1690. DOI: 10.18240/ ijo.2016.11.24

Tangamornsuksan W., Lohitnavy M. Association between HLA-B*5901 and methazolamide-induced Stevens-Johnson syndrome/toxic epidermal necrolysis: a systematic review and meta-analysis. Pharmacogenomics J. 2019 Jun;19(3):286–294. DOI: 10.1038/s41397-018-0052-2

Sweeney K.R., Chapron D.J., Brandt J.L., Gomolin I.H., Feig P.U., Kramer P.A. Toxic interaction between acetazolamide and salicylate: case reports and a pharmacokinetic explanation. Clin. Pharmacol. Ther. 1986 Nov;40(5):518–524. DOI: 10.1038/clpt.1986.217

Schwenk M.H., St Peter W.L., Meese M.G., Singhal P.C. Acetazolamide toxicity and pharmacokinetics in patients receiving hemodialysis. Pharmacotherapy. 1995 JulAug;15(4):522–527. PMID: 7479208

Liu Y., Zhao J., Zhong X., Wei Q. and Huang Y. Efficacy and Safety of Brinzolamide as Add-On to Prostaglandin Analogues or β-Blocker for Glaucoma and Ocular Hypertension: A Systematic Review and Meta-Analysis. Front. Pharmacol. 2019;10:679. DOI: 10.3389/fphar.2019.00679

Hong E., Ahn S., Lim H. The effect of oral acetazolamide on cystoid macular edema in hydroxychloroquine retinopathy: a case report. BMC Ophthalmol 2017 Jul 12;17(1):124. DOI: 10.1186/s12886-017-0517-0

Suzuki T., Hayakawa K., Nakagawa Y. Topical dorzolamide for macular edema in the early phase after vitrectomy and epiretinal membrane removal Clinical Ophthalmology 2013:7:549–553.

Kawai K., Ohashi H., Suzuki T., Kitagaki H., Fujisawa S. Effect of anti-glaucoma drugs on inflammatory cytokine production by human and murine peripheral blood mononuclear cells. Nippon Ganka Gakkai Zasshi. 2010;114:669–677 (In Japanese).

Wolfensberger T.J. The role of carbonic anhydrase inhibitors in the management of macular edema. Doc Ophthalmol. 1999;97:387–397.

Mirshahi A., Tadayoni R., Mohsenzadeh N. Efficacy of adjuvant topical timolol– dorzolamide with intravitreal bevacizumab injection in diabetic macular edema: A contralateral eye study. J.Curr Ophthalmol. 2019 Jun;31(2):168–171. DOI: 10.1016/j.joco.2019.01.008

Курышева Н.И., Азизова О.А., Пирязев А.П. Антирадикальная и антиоксидантная активность ингибиторов карбоангидразы для местного лечения глаукомы. Российский офтальмологический журнал 2011;4(3):55–61.

Kurysheva N.I., Azizova O.A., Piryazev A.P. Antiradical and antioxidant activity of carbonic anhydrase inhibitors for the local treatment of glaucoma. Russian ophthalmological journal = Rossiyskiy oftal’mologicheskiy zhurnal. 2011;4(3):55–61 (In Russ.).

Курышева Н.И., Азизова О.А. Сравнительное исследование антиоксидантной активности комбинированных препаратов для местного лечения глаукомы. Российский офтальмологический журнал 2013;6(2):48–51.

Kurysheva N.I., Azizova O.A. A comparative study of the antioxidant activity of combination drugs for the local treatment of glaucoma. Russian ophthalmological journal = Rossiyskiy oftal’mologicheskiy zhurnal. 2013;6(2):48–51 (In Russ.).

Курышева Н.И., Азизова О.А., Пирязев А.П. Антиоксидантная активность фиксированнной комбинации дорзоламида с тимололом в аспекте нейропротекции при глаукоме. Офтальмология 2012;9(4):47–51. DOI: 10.18008/1816-5095-2012-4-47-51

Kurysheva N.I., Azizova O.A., Piryazev A.P. Antioxidant activity of a fixed combination of dorzolamide with timolol in the aspect of neuroprotection in glaucoma. Оphthalmology in Russia = Oftal’mologiya. 2012;9(4):47–51 (In Russ.). DOI: 10.18008/1816-5095-2012-4-47-51

Moreno V., Medina J., Pinazo R. Antioxidant status modifications by topical administration of dorzolamide in primary open-angle glaucoma Eur J Ophthalmol 2009;19(4):565–571. DOI: 10.1177/112067210901900408

Sacca S., La Maestra S., Micale R. Ability of dorzolamide hydrochloride and timolol maleate to target mitochondria in glaucoma therapy Arch Ophthalmol. 2011 Jan;129(1):48–55. DOI: 10.1001/archophthalmol.2010.324

Nocentini A., Ferraroni M., Carta F., Ceruso M., Gratteri P., Lanzi C. Benzenesulfonamides incorporating flexible triazole moieties are highly effective arbonic anhydrase inhibitors: synthesis and kinetic, crystallographic, computational, and intraocular pressure lowering investigations. J Med Chem 2016;59(23):10692–e10704. DOI: 10.1021/acs.jmedchem.6b01389

Long D.D., Frieman B., Hegde S.S., Hill C.M., Jiang L., Kintz S. A multivalent approach towards linked dual-pharmacology prostaglandin F receptor agonist/carbonic anhydrase-II inhibitors for the treatment of glaucoma. Bioorg Med Chem Lett 2013;23:939–e943. DOI: 10.1016/j.bmcl.2012.12.058

Chiaramonte N., Bua S., Ferraroni M., Nocentini A., Bonardi A., Bartolucci G. et al. 2-Benzylpiperazine: a new scaffold for potent human carbonic anhydrase inhibitors. Synthesis, enzyme inhibition, enantioselectivity, computational and crystallographic studies and in vivo activity for a new class of intraocular pressure lowering agents. Eur J Med Chem 2018;151:363–e375. DOI: 10.1016/j.ejmech.2018.04.002

Steele R.M., Benedini F., Biondi S., Borghi V., Carzaniga L., Impagnatiello F., et al. Nitric oxide-donating carbonic anhydrase inhibitors for the treatment of openangle glaucoma. Bioorg Med Chem Lett 2009;19:6565–e6570. DOI: 10.1016/j.bmcl.2009.10.036

Haefliger I., Flammer J. Nitric Oxide and Endothelin in the Pathogenesis of Glaucoma, Survey of Ophthalmology, 1999;43(1):551–558. DOI: 10.1016/s0039-6257(99)00026-0

Курышева Н.И. Гемоперфузия глаза и глаукома. Гринлайт. 2014. 138 с.

Kurysheva N.I. Eye hemoperfusion and glaucoma. Greenlight. 2014. 138 p. (In Russ.).

Курышева Н.И., Томилова И.К., Деев А.А., Назаров С.Б. Оксид азота в патогенезе катаракты и глаукомы. Вестник офтальмологии. 2001;5:5–7.

Kurysheva N.I., Tomilova I.K., Deev A.A., Nazarov S.B. Nitric oxide in the pathogenesis of cataracts and glaucoma. Annals of Ophthalmology = Vestnik oftal’mologii. 2001;5:5–7 (In Russ.).

Mincione F., Benedini F., Biondi S., Cecchi A., Temperini C., Formicola G. Synthesis and crystallographic analysis of new sulfonamides incorporating NO-donating moieties with potent antiglaucoma action. Bioorg Med Chem Lett 2011;21:3216– e3221. DOI: 10.1016/j.bmcl.2011.04.046

Fabrizi F., Mincione F., Somma T., Scozzafava G., Galassi F., Masini E. A new approach to antiglaucoma drugs: carbonic anhydrase inhibitors with or without NO donating moieties. Mechanism of action and preliminary pharmacology. J Enzym Inhib Med Chem 2012;27:138–e147. DOI: 10.3109/14756366.2011.597749

Bozdag M., Altamimi A.S.A., Vullo D., Supuran C.T., Carta F. State of the art on carbonic anhydrase modulators for biomedical purposes. Curr Med Chem 2018;25. DOI: 10.2174/0929867325666180622120625

Carta F., Aggarwal M., Maresca A., Scozzafava A., McKenna R., Masini E., Supuran C.T. Dithiocarbamates strongly inhibit carbonic anhydrases and show antiglaucoma action in vivo. J Med Chem 2012;55(4):1721–1730. DOI: 10.1021/jm300031j

The authors declare that there are no conflicts of interest present.